Recent evidence remains mixed: a meta-analysis of randomized trials reported a slight increase in pancreatitis risk among GLP-1 RA users, whereas a large real-world analysis found no excess risk in a comorbidity-free population [29, 30]. However, direct comparisons across these studies are limited by differences in design, patient selection, and follow-up duration. In contrast, our real-world cohort, without strict eligibility restrictions, may capture risk emerging in specific subpopulations. This evidence concerns the gene GLP1R and pancreatitis.